Polaryx Therapeutics, Inc. Nov 22, 2026 Copy link Polaryx Therapeutics Highlights Participation in NCL Scientific Conference and NTSAD Imagine & Believe Event Scientific presentation and patient advocacy engagement follow activation of the first clinical trial site for SOTERIA Business
Polaryx Therapeutics, Inc. Nov 9, 2026 Copy link Polaryx Therapeutics Activates First Clinical Trial Site for SOTERIA Phase 2 Basket Trial of PLX-200 Boys Town National Research Hospital in Nebraska becomes first activated site in study targeting four rare pediatric Business
Polaryx Therapeutics, Inc. Sep 1, 2026 Copy link Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical Business
Polaryx Therapeutics, Inc. May 28, 2026 Copy link Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial PARAMUS, NJ, May 28, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), Business